Array Biopharma (ARRY), Kasei Pharma Enter Collaboration


Array BioPharma Inc. (Nasdaq: ARRY) and Asahi Kasei Pharma Corporation today announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for pain, inflammation and other non-cancer indications. Array retains the right for all compounds for all indications outside of Asia. Within Asia, Array retains the right to cancer indications for all compounds, excluding those compounds being developed by Asahi Kasei Pharma, including ARRY-954.

Subscribe to get the latest news